Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

CTLA-4 Ig

Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses

OTHER

Placebo

Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses

Trial Locations (13)

10032

Columbia University, Naomi Berrie Diabetes Center, New York

15213

University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh

33136

University of Miami, Miami

55455

University of Minnesota, Minneapolis

80045

The Barbara Davis Center for Childhood Diabetes, Aurora

90027

Childrens Hospital Los Angeles, Los Angeles

94143

University of California - San Francisco, San Francisco

94305

Stanford University, Stanford

98101

Benaroya Research Institute, Seattle

32610-0296

University of Florida, Gainesville

02215

Joslin Diabetes Center, Boston

75235-8858

University of Texas, Southwestern Medical School, Dallas

M5G-1X8

The Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

American Diabetes Association

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00505375 - Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter